BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth Rates

  October 12, 2026

   · 

  6 min read
• Press Releases

  Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study

  October 12, 2026

   · 

  3 min read
• Press Releases

  Novo Nordisk A/S - share repurchase programme - October 12, 2026

  October 12, 2026

   · 

  2 min read
• Press Releases

  ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

  October 12, 2026

   · 

  17 min read
• Press Releases

  Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

  October 12, 2026

   · 

  8 min read
• Press Releases

  Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

  October 12, 2026

   · 

  6 min read
• Press Releases

  Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

  October 12, 2026

   · 

  17 min read
• Press Releases

  Kraig Biocraft Laboratories Files for Expanded Investment License to Fuel Spider Silk Production Growth

  October 12, 2026

   · 

  4 min read
• Press Releases

  NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

  October 12, 2026

   · 

  5 min read
• Press Releases

  Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

  October 12, 2026

   · 

  7 min read